// App-Quantinova.ai

619 : Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis

Researchers

Presenter

  • Peter Nash

Principal Investigators

  • Laura C Coates

  • Roy Fleischmann

  • Kim Papp

  • Juan J. Gomez-Reino

  • Keith S Kanik

  • Cunshan Wang

  • Joseph Wu

  • Thijs Hendrikx

  • William C Ports

Medical Centers

  • Department of Medicine, University of Queensland, Brisbane, Queensland, Australia

  • Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

  • Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada

  • Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

Locations

  • Australia

  • United Kingdom

  • United States

  • Canada

  • Spain

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • NA

Study Id's

  • NCT01877668]

  • NCT01882439]

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved